^
    BIOMARKER:

    PIK3CA mutation

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K




    Show legend

    Include preclinical:
    HER2 Positive Breast Cancer
    Breast Cancer
    Squamous Cell Carcinoma of Head and Neck
    Solid Tumor
    Colorectal Cancer
    Non Small Cell Lung Cancer
    Cervical Cancer
    Gastric Cancer
    Hormone Receptor Positive Breast Cancer
    Triple Negative Breast Cancer
    HER2 Negative Breast Cancer
    Estrogen Receptor Positive Breast Cancer
    Ovarian Cancer
    Head and Neck Cancer
    Uterine Cancer
    Urothelial Cancer
    Lung Non-Small Cell Squamous Cancer
    Liposarcoma
    Ampulla of Vater Carcinoma
    Cholangiocarcinoma
    Lung Adenocarcinoma
    Pancreatic Ductal Adenocarcinoma
    Lung Cancer
    Melanoma
    Thyroid Gland Carcinoma
    Adenoid Cystic Carcinoma
    Endometrial Cancer
    Colon Cancer
    alpelisib
    everolimus
    GDC-0032
    copanlisib
    GDC-0084
    trastuzumab + pertuzumab + alpelisib
    atezolizumab + cobimetinib
    MEN1611
    temsirolimus
    CYH33
    trastuzumab + alpelisib
    U3-1402
    capivasertib
    pembrolizumab
    AN2025
    everolimus + exemestane
    bevacizumab
    ribociclib
    fulvestrant + anastrozole
    palbociclib
    camrelizumab + rivoceranib
    trastuzumab + MEN1611
    letrozole
    trametinib + dabrafenib
    alpelisib + tipifarnib
    nivolumab
    avelumab + binimetinib
    anlotinib + sintilimab
    cetuximab + alpelisib
    trastuzumab + alpelisib + LJM-716
    ARQ 751
    ACR-368 + LY3023414
    everolimus + SNX-631
    RG7440
    panitumumab
    neratinib
    lapatinib
    trastuzumab
    erlotinib
    pertuzumab + ado-trastuzumab emtansine
    ensartinib
    osimertinib
    cetuximab
    ado-trastuzumab emtansine
    cisplatin + paclitaxel
    docetaxel + cyclophosphamide + eribulin mesylate
    trastuzumab-pkrb
    MK-2206
    tipifarnib
    cetuximab + AZD8055
    vemurafenib
    alpelisib + abemaciclib
    neratinib + copanlisib
    epirubicin
    LY3023414
    alpelisib + ribociclib
    palbociclib + alpelisib
    CC-115
    PP242
    crizotinib + sunitinib
    gefitinib + everolimus
    GDC-0941
    ribociclib + VRx-510
    palbociclib + VRx-510
    CCT128930
    AVTX-006
    CB-228
    PF-05212384 + PD-0325901
    temsirolimus + MK-2206
    RTB101
    TCbHP
    HER2 inhibitor
    PD1 inhibitor
    THP
    PI3K inhibitor + EZH2 inhibitor
    FOLFOX
    Immunotherapy
    PI3K inhibitor
    CDK4 inhibitor + CDK6 inhibitor
    CAPOX
    mTORC1 inhibitor
    EZH2 inhibitor